about
Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East AsiaHexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.Management of trypanosomiasis and leishmaniasisEffect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleriRecent developments and future prospects in the treatment of visceral leishmaniasisTargeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesDrug resistance analysis by next generation sequencing in LeishmaniaRecent developments in drug discovery for leishmaniasis and human African trypanosomiasisA Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment OutcomeUsing existing drugs as leads for broad spectrum anthelmintics targeting protein kinasesCurrent challenges in treatment options for visceral leishmaniasis in India: a public health perspectivePlasticity of the Leishmania genome leading to gene copy number variations and drug resistanceMiltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendationsAntiparasitic therapyPentavalent antimonials: new perspectives for old drugsDevelopments in the treatment of visceral leishmaniasisNeglected tropical diseasesMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisClinical status of agents being developed for leishmaniasisIncreasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncomplianceIn-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleriFailure of miltefosine in visceral leishmaniasis is associated with low drug exposureUnresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.Tamoxifen is effective in the treatment of Leishmania amazonensis infections in miceCost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinentGenetic polymorphisms and drug susceptibility in four isolates of Leishmania tropica obtained from Canadian soldiers returning from AfghanistanIn vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasitesDrug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasisIn vitro and in vivo activity of an organic tellurium compound on Leishmania (Leishmania) chagasiFive-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, IndiaIn vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasisIn silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoniEfficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label studyDecline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in IndiaEfficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized TrialDrug resistance in leishmaniasisDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Analyzing time-to-event data in a clinical trial when an unknown proportion of subjects has experienced the event at entry.Leishmaniasis.Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
P2860
Q21132005-910984FB-E3EE-4BC0-86DB-2FD944BB7064Q24538756-23092DA7-3164-464C-8F98-298FCC89850BQ24596889-EBFD6032-F9FC-4211-A0B3-ECCE8E1DAC88Q24648204-7FB2E19C-EC7D-4628-B26C-C7E55BDCC905Q26740563-91A94887-1CF6-45C6-86A6-B6DD7E11DB7FQ26829652-462CD873-3E20-4FDC-A505-7CCBCADFB557Q26851222-25CCD8A5-A49B-4BF2-9598-1E8F75CF67E6Q27011766-3A35A62F-8353-45B7-A649-5882E143BD89Q27303693-AA31BE3F-46F5-4BE8-9890-7370639B6798Q27336465-FC74E3BB-0FE9-4004-95BC-931EAAC93403Q28073426-F75ACEEE-6FEF-4D2C-BD8B-D29D7212008EQ28074697-BED660D1-0F72-4D59-B72F-6D2DD31AC45DQ28088410-EB1EF5FD-ADDF-4BD4-BE79-217CFE6562FEQ28239164-EFE19415-6AA0-4A01-90DB-DF447255A5DEQ28253055-2C1EA931-7DF4-4DA0-AAA9-21D84E9209FCQ28256441-421E71DA-C931-4570-90F7-FC0B9982D165Q28267545-AB371AD6-D115-49BB-8D12-DF92DCD9F1D2Q28271849-EDAA1823-AE5E-43CE-AAFE-F89013044880Q28279390-E4BADD9C-2AC5-47B0-A2D8-CEF8A68D4472Q28285948-9F6A9F9A-456C-4D12-9A38-DADA84AA7D07Q28304841-D9343172-AED2-4DFA-B7B2-5B159C493528Q28306178-1356FDB6-31B3-46F4-89CE-9649E69E7993Q28468760-608C088E-24C4-4EA9-B21A-97FEEF396629Q28472920-B49D168D-BF86-44BF-818B-A32A7C9556B4Q28475431-74B4498C-8BCD-4F18-A9DD-31849FDF21B3Q28478944-CFAA5863-9674-4782-9C5E-7036715B40CDQ28482212-ECC190F1-6C46-4F70-A182-73E7C32468A7Q28483875-D7897507-1F7C-4721-BA94-FB43007DC0EBQ28484948-E07D3193-CA64-4F7D-BA25-281725689E92Q28538265-E22EE4C8-5C36-4702-A5CD-1226E83887B9Q28540828-D21EFC4D-8AF1-499D-8F43-87062F77AF29Q28542999-DBC0370F-8EF6-4A98-961C-275CA2482DA2Q28543060-3DC2BB71-06BB-4D50-9598-F64D3D85880DQ28550454-769E0975-C65F-4AB0-9586-45EAE4A35340Q28554069-38B48253-684D-4408-9F59-F40CCC961F8BQ29616242-396EAA84-4CD1-4575-A71D-61FE1BCBBFAAQ30275257-6A4D870B-CC79-438B-AEAE-4871E327918EQ30936764-991EEEE8-28E0-46CE-8650-7819EC5C85B1Q31107638-8024D7E2-A5E4-49E5-8DA8-F7C1C077C8DCQ33637372-553D957C-F35D-4290-A6E0-6630607A8C54
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Oral miltefosine for Indian visceral leishmaniasis.
@ast
Oral miltefosine for Indian visceral leishmaniasis.
@en
Oral miltefosine for Indian visceral leishmaniasis.
@nl
type
label
Oral miltefosine for Indian visceral leishmaniasis.
@ast
Oral miltefosine for Indian visceral leishmaniasis.
@en
Oral miltefosine for Indian visceral leishmaniasis.
@nl
prefLabel
Oral miltefosine for Indian visceral leishmaniasis.
@ast
Oral miltefosine for Indian visceral leishmaniasis.
@en
Oral miltefosine for Indian visceral leishmaniasis.
@nl
P2093
P356
P1476
Oral miltefosine for Indian visceral leishmaniasis.
@en
P2093
Anthony Bryceson
C P Thakur
Christina Fischer
Herbert Sindermann
Jonathan Berman
Juergen Engel
Klaus Junge
P304
P356
10.1056/NEJMOA021556
P407
P50
P577
2002-11-01T00:00:00Z